Denali Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application $(BLA.AU)$ for tividenofusp alfa, a treatment for Hunter syndrome (MPS II), a rare genetic disorder. The FDA has granted Priority Review for the application, setting a target decision date of January 5, 2026, for potential accelerated approval. Tividenofusp alfa is designed to deliver the missing enzyme to the entire body and cross the blood-brain barrier into the brain, marking a potential significant advancement in enzyme replacement therapy for Hunter syndrome. This development also represents a pivotal milestone for Denali's TransportVehicle™ platform aimed at treating various lysosomal storage diseases and neurodegenerative disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.